Hartley and colleagues reported a case of tumor-induced osteomalacia caused by PMT, in which the patient participated a clinical trial that studied infigratinib, an FGFR1-3 inhibitor (NCT02160041), and experienced a dramatic response, with FGF23 levels decreasing to almost one-tenth in the first 24 h and returning to normal after 2 weeks [52]. Here, FGF23 is linked to osteomalacia.